drugset / Trial / NCT05853575
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
RandomizedSequentialOpen-labelTreatment
Summary
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.
Timeline
- Start
- 2024-02-16
- Primary completion
- 2026-07-30
- Completion
- 2026-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adagrasib | Small molecule | 400 mg | — |
| Subject | Adagrasib | Small molecule | 600 mg | — |